June 20, 2021

SpywareNews.com

Dedicated Forum to help removing adware, malware, spyware, ransomware, trojans, viruses and more!

A New Type Of COVID-19 Vaccine Could Debut Soon

A New Type Of COVID-19 Vaccine Could Debut Soon

“A new kind of COVID-19 vaccine could be available as soon as this summer,” reports NPR:

It’s what’s known as a protein subunit vaccine. It works somewhat differently from the current crop of vaccines authorized for use in the U.S. but is based on a well-understood technology and doesn’t require special refrigeration.

In general, vaccines work by showing people’s immune systems something that looks like the virus but really isn’t. Consider it an advance warning; if the real virus ever turns up, the immune system is ready to try to squelch it. In the case of the coronavirus, that “something” is one of the proteins in the virus — the spike protein. The vaccines made by Johnson & Johnson, Moderna and Pfizer contain genetic instructions for the spike protein, and it’s up to the cells in our bodies to make the protein itself.

The first protein subunit COVID-19 vaccine to become available will likely come from the biotech company, Novavax. In contrast to the three vaccines already authorized in the U.S., it contains the spike protein itself — no need to make it, it’s already made — along with an adjuvant that enhances the immune system’s response, to make the vaccine even more protective.

Protein subunit vaccines made this way have been around for a while. There are vaccines on the market for hepatitis B and pertussis based on this technology.

And meanwhile, the article points out, there’s also another company — the pharmaceutical giant Sanofi — that’s also working on its own protein subunit vaccine against the coronavirus.

Read more of this story at Slashdot.

“A new kind of COVID-19 vaccine could be available as soon as this summer,” reports NPR:

It’s what’s known as a protein subunit vaccine. It works somewhat differently from the current crop of vaccines authorized for use in the U.S. but is based on a well-understood technology and doesn’t require special refrigeration.

In general, vaccines work by showing people’s immune systems something that looks like the virus but really isn’t. Consider it an advance warning; if the real virus ever turns up, the immune system is ready to try to squelch it. In the case of the coronavirus, that “something” is one of the proteins in the virus — the spike protein. The vaccines made by Johnson & Johnson, Moderna and Pfizer contain genetic instructions for the spike protein, and it’s up to the cells in our bodies to make the protein itself.

The first protein subunit COVID-19 vaccine to become available will likely come from the biotech company, Novavax. In contrast to the three vaccines already authorized in the U.S., it contains the spike protein itself — no need to make it, it’s already made — along with an adjuvant that enhances the immune system’s response, to make the vaccine even more protective.

Protein subunit vaccines made this way have been around for a while. There are vaccines on the market for hepatitis B and pertussis based on this technology.

And meanwhile, the article points out, there’s also another company — the pharmaceutical giant Sanofi — that’s also working on its own protein subunit vaccine against the coronavirus.

Read more of this story at Slashdot.